With plenty of GLP-1 money to spend, Eli Lilly and Co. is buying Verve Therapeutics Inc. and its gene-editing program for ...

Yum Brands named Chief Financial Officer Chris Turner as its next chief executive. Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion Deal would add a potential treatment for ...

INDIANAPOLIS — Eli Lilly filed lawsuits against compounding pharmacies and an Indianapolis weight loss company over the use of Zepbound and Mounjaro. On April 1, 2025, Lilly filed lawsuits against two ...

Eli Lilly & Co. aims to offer a one-and-done heart-disease medicine by paying up to $1.3 billion for Verve Therapeutics Inc., ...

Eli Lilly will buy Boston-based Verve Therapeutics, Inc. in a billion dollar deal with plans to advance Verve's new line of ...

Eli Lilly (LLY) will acquire Verve Therapeutics (VERV) for up to $13.5/share, aiming to revolutionize cholesterol treatment.

B Verve Therapeutics (VERV) acquisition offers investors a 70%+ premium. See why I think this deal is beneficial to both ...

NEW YORK (AP) — U.S. stock indexes are drifting lower on Tuesday, while oil prices rise again.

Eli Lilly agreed to acquire Verve Therapeutics for about $1 billion upfront, adding a potential treatment for cardiovascular ...

Yum Brands named Chief Financial Officer Chris Turner as its next chief executive. Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion Deal would add a potential treatment for ...

Boston-based Verve Therapeutics is a Nasdaq-traded company focused on genetic medicines for cardiovascular disease.